Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

E Ritz, G C Viberti, L M Ruilope, A J Rabelink, J L Izzo Jr, S Katayama, S Ito, A Mimran, J Menne, L C Rump, A Januszewicz, H Haller, E Ritz, G C Viberti, L M Ruilope, A J Rabelink, J L Izzo Jr, S Katayama, S Ito, A Mimran, J Menne, L C Rump, A Januszewicz, H Haller

Abstract

Aims/hypothesis: In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk.

Methods: At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed.

Results: Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r(s) = 0.19); HbA(1c) (r(s) = 0.18); mean 24 h systolic BP (r(s) = 0.16); fasting blood glucose (r(s) = 0.16); night-time diastolic BP (r(s) = 0.12); office systolic BP, sitting (r(s) = 0.11), standing (r(s) = 0.10); estimated GFR (r(s) = 0.10); heart rate, sitting (r(s) = 0.10); haemoglobin (r(s) = -0.10); triacylglycerol (r(s) = 0.09); and uric acid (r(s) = -0.08; all p <or= 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women).

Conclusions/interpretation: Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention.

Trial registration: ClinicalTrials.gov ID no.: NCT00185159

Funding: This study was sponsored by Daichii-Sankyo.

Figures

Fig. 1
Fig. 1
Relationship of UACR with quintiles of night-time SBP (a), HbA1c (b) and eGFR (c)

References

    1. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens. 2006;15:631–636. doi: 10.1097/01.mnh.0000247496.54882.3f.
    1. Senator H. Albuminuria in health and disease. London: The New Sydenham Society; 1884.
    1. Mogensen CE. Urinary albumin excretion in diabetes. Lancet. 1971;2:601–602.
    1. Mogensen C. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–360.
    1. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430–1432. doi: 10.1016/S0140-6736(82)92450-3.
    1. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med. 2003;139:901–906.
    1. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract. 2000;49:187–194. doi: 10.1016/S0168-8227(00)00155-8.
    1. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969–975. doi: 10.1161/CIRCULATIONAHA.105.538132.
    1. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int. 2006;70:1214–1222. doi: 10.1038/sj.ki.5001729.
    1. Gallego PH, Gilbey AJ, Grant MT, et al. Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005;18:879–885.
    1. Perrin NE, Torbjornsdotter TB, Jaremko GA, Berg UB. Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes. Pediatr Nephrol. 2004;19:1004–1013. doi: 10.1007/s00467-004-1509-x.
    1. Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care. 2006;29:2072–2077. doi: 10.2337/dc06-0239.
    1. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004;47:1020–1028. doi: 10.1007/s00125-004-1413-8.
    1. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328:1105–1109. doi: 10.1136/bmj.38070.450891.FE.
    1. Yamada T, Komatsu M, Komiya I, et al. Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa Study. Diabetes Care. 2005;28:2733–2738. doi: 10.2337/diacare.28.11.2733.
    1. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study. J Hypertens. 2006;24:403–408. doi: 10.1097/01.hjh.0000202820.56201.e6.
    1. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–1951. doi: 10.1056/NEJMoa042167.
    1. Strippoli GF, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, CD006257
    1. Strain WD, Chaturvedi N, Dockery F, et al. Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am J Hypertens. 2006;19:889–896. doi: 10.1016/j.amjhyper.2006.01.009.
    1. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797–805. doi: 10.1056/NEJMoa013410.
    1. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int. 2005;68:1250–1257. doi: 10.1111/j.1523-1755.2005.00521.x.
    1. Afsar B, Sezer S, Elsurer R, Ozdemir FN. Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit. 2007;12:133–139. doi: 10.1097/MBP.0b013e3280b08379.
    1. Tamura K, Tsurumi Y, Sakai M, et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens. 2007;29:31–42. doi: 10.1080/10641960601096760.
    1. Nakano S, Ito T, Furuya K, et al. Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects. Hypertens Res. 2004;27:647–656. doi: 10.1291/hypres.27.647.
    1. Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL. Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care. 2007;30:1255–1260. doi: 10.2337/dc06-2131.
    1. Anan F, Masaki T, Umeno Y, et al. Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77:414–419. doi: 10.1016/j.diabres.2007.01.009.
    1. Tanaka M, Babazono T, Takeda M, Iwamoto Y. Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res. 2006;29:345–352. doi: 10.1291/hypres.29.345.
    1. Knudsen ST, Jeppesen P, Frederiksen CA, et al. Endothelial dysfunction, ambulatory pulse pressure and albuminuria are associated in type 2 diabetic subjects. Diabet Med. 2007;24:911–915. doi: 10.1111/j.1464-5491.2007.02197.x.
    1. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001). JAMA 285:2486–2497
    1. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes. 2006;55:1456–1462. doi: 10.2337/db05-1484.
    1. Franciosi M, Pellegrini F, Sacco M, et al. Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol. 2007;2:984–991. doi: 10.2215/CJN.01190307.
    1. Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension. 2005;45:1125–1130. doi: 10.1161/01.HYP.0000167151.52825.11.
    1. Meigs JB, D’Agostino RB, Sr, Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002;25:977–983. doi: 10.2337/diacare.25.6.977.
    1. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care. 2002;25:1410–1417. doi: 10.2337/diacare.25.8.1410.
    1. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Am J Kidney Dis. 2004;44:792–798. doi: 10.1016/S0272-6386(04)01079-0.
    1. Wang XL, Lu JM, Pan CY, Tian H, Li CL. A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med. 2005;22:332–335. doi: 10.1111/j.1464-5491.2004.01408.x.
    1. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174.
    1. Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens. 2006;24:1157–1163. doi: 10.1097/.
    1. de Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007;18:235–243. doi: 10.1681/ASN.2006040394.
    1. Tseng CH. Waist-to-height ratio is independently and better associated with urinary albumin excretion rate than waist circumference or waist-to-hip ratio in Chinese adult type 2 diabetic women but not men. Diabetes Care. 2005;28:2249–2251. doi: 10.2337/diacare.28.9.2249.
    1. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–2483. doi: 10.1056/NEJMra054415.
    1. Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care. 2006;29:1024–1030. doi: 10.2337/dc05-2201.
    1. Thomas MC, Rosengard-Barlund M, Mills V, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care. 2006;29:317–322. doi: 10.2337/diacare.29.02.06.dc05-0809.
    1. Tseng CH. Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kidney Int. 2005;67:1547–1553. doi: 10.1111/j.1523-1755.2005.00235.x.
    1. Tseng CH. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int. 2005;68:796–801. doi: 10.1111/j.1523-1755.2005.00459.x.
    1. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes. 2002;51:1580–1587. doi: 10.2337/diabetes.51.5.1580.
    1. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27:195–207. doi: 10.1016/j.semnephrol.2007.01.012.
    1. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47:793–800. doi: 10.2337/diabetes.47.5.793.
    1. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151(11–20):W3–W4.
    1. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003;14:641–647. doi: 10.1097/01.ASN.0000051594.21922.99.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren